NCT00129831View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
COPD
Interventions
DRUG

QAB149

Trial Locations (2)

83704

Radiant Research, Boise

92024

Radiant Research, Encinitas

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00129831 - Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter